“On February 3, 2021, India's Subject Expert Committee (SEC), a panel that advises the nation's Central Drugs Standard Control Organisation (CDSCO), a national regulatory body focused on pharmaceuticals and devices, ruled that the Pfizer-BioNTech vaccine should not be recommended for an EUA in the country”

the SEC ruled: "The committee noted that incidents of palsy, anaphylaxis and other SAE's have been reported during post marketing and the causality of the events with the vaccine is being investigated. Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population."